Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1 (5-Year IF – 2.0)
Journal Citation Indicator (JCI) (2023) – 0.4
Scopus CiteScore – 3.7 (CiteScore Tracker 3.3)
Index Copernicus  – 161.11; MNiSW – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2013, vol. 22, nr 3, May-June, p. 403–409

Publication type: original article

Language: English

An Evaluation of Nitric Oxide, Folate, Homocysteine Levels and Lipid Peroxidation in Postmenopausal Osteoporosis

Ocena stężenia tlenku azotu, kwasu foliowego, homocysteiny i peroksydacji lipidów w osteoporozie pomenopauzalnej

Veysi Akpolat1,F, H. Murat Bilgin2,A,B,D,E, M. Yusuf Celik3,C, Mahmut Erdemoglu4,B, Birgul Isik5,A,B

1 Department of Biophysics, Bone Mineral Densitometry Unit, Faculty of Medicine, Dicle University, Turkey

2 Department of Physiology, Faculty of Medicine, Dicle University, Turkey

3 Department of Biostatistics, Faculty of Medicine, Dicle University, Turkey

4 Department of Obstetrics and Gynecology, Faculty of Medicine, Dicle University, Turkey

5 Department of Biochemistry, Faculty of Medicine, Dicle University, Turkey

Abstract

Abstract
Objectives. In the current study, the risk coefficients of nitric oxide (NO), folate, homocysteine levels and lipid peroxidation in postmenopausal osteoporotic women were determined.
Material and Methods. Bone mineral density was determined by dual-energy X-ray absorptiometry. The levels of serum lipid peroxidation products such as the thiobarbituric acid adduct of malondialdehyde (MDA) were measured spectrophotometrically. Plasma folate and homocysteine (Hcy) levels were measured by enzyme chemi- luminescence immunoassay. Plasma nitrite levels were measured with the Griess reaction
Results. The odds ratios and 95% Confidence Intervals (CI) of the variables MDA, folate, NO, body-mass index (BMI), menopause age and age were found significant. MDA, NO and folate variables were found statistically sig- nificant in the analysis of receiver operating charecteristic (ROCs). The areas under the curve (AUCs, 95% CI) of MDA, NO and folate were found to be statistically significant.
Conclusions. The current study indicates that NO, MDA and folate are risk variables for postmenopausal osteo- porosis (Adv Clin Exp Med 2013, 22, 3, 403–409).
 

Streszczenie

Cel pracy. W pracy oceniono czynniki ryzyka, takie jak stężenie tlenku azotu (NO), kwasu foliowego, homocyste- iny i peroksydację lipidów, w okresie pomenopauzalnym u kobiet chorych na osteoporozę.
Materiał i metody. Gęstość mineralną kości zmierzono za pomocą dwuwiązkowej absorpcjometrii rentgenowskiej. Stężenia produktów peroksydacji lipidów, takich jak addukt aldehydu malonowego (MDA) i kwasu tiobarbituro- wego, zmierzono spektrofotometrycznie. Stężenie kwasu foliowego i homocysteiny (Hcy) zmierzono za pomocą testu immunoenzymatycznego chemiluminescencji. Stężenie azotynów w osoczu zmierzono za pomocą reakcji Griessa.
Wyniki. Ilorazy szans i 95% przedziały ufności (CI) zmiennych MDA, kwas foliowy, NO, wskaźnik masy ciała (BMI), wiek menopauzy oraz wiek były znaczące. Stwierdzono, że zmienne MDA, NO i kwas foliowy są istotne statystycznie w analizie krzywej ROC. Obszary pod krzywą (AUC, 95% CI) MDA, NO i kwasu foliowego okazały się istotne statystycznie.Wnioski. Wyniki badania wskazują, że NO, MDA i kwas foliowy są czynnikami ryzyka osteoporozy pomenopau- zalnej (Adv Clin Exp Med 2013, 22, 3, 403–409).

 

Key words

Key words: nitric oxide, folate, malondialdehyde, homocysteine, osteoporosis.

Słowa kluczowe

Słowa kluczowe: tlenek azotu, kwas foliowy, aldehyd malonowy, homocysteina, osteoporoza.

References (37)

  1. Manolagas SC: Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 2000, 21, 115–137.
  2. Christodoulou C, Cooper C: What is osteoporosis? Postgrad Med J 2003, 79, 133–138.
  3. Tyagi N, Kandel M, Munjal C, Qipshidze N, Vacek JC, Pushpakumar SB et al.: Homocysteine mediated decrease in bone blood flow and remodeling: role of folic acid. J Orthop Res 2011, 29(10), 1511–1516.
  4. Alley RA, Chen EL, Beyer TD, Prinz RA: Does homocysteine contribute to bone disease in hyperparathyroidism? Am J Surg 2008, 195, 374–377.
  5. Banfi G, Iorio EL, Corsi MM: Oxidative stress, free radicals and bone remodeling. Clin Chem lab Med 2008, 46, 1550–1555.
  6. Woo KS, Chook P, Lolin YI, Sanderson JE, Metreweli C, Celermajer DS: Folic acid improves arterial endothelial function in adults with hyperhomocystinemia. J Am Coll Cardiol 1999, 34, 2002–2006.
  7. Herrmann M, Taban-Shomal O, Muller S, Gunter L, Hübner U, Böhm M et al.: Hyperhomocysteinemia – The biochemical link between a weak heart and brittle bones? Clin lab 2006, 52, 137–147.
  8. Dhonukshe-Rutten RA, Pluijm SM, de Groot LC, Lips P, Smit JH, van Staveren WA: Homocysteine and vitamin B12 status relate to bone turnover markers, broadband ultrasound attenuation, and fractures in healthy elderly people. J Bone Miner Res 2005, 20, 921–929.
  9. Van’t Hof RJ, Ralston SH: Nitric oxide and bone. Immunology 2001, 103, 255–261.
  10. Caballero-Alias AM, Loveridge N, Lyon A, Das-Gupta V, Pitsillides A, Reeve J: NOS isoforms in adult human osteocytes: multiple pathways of NO regulation? Calcif Tissue Int 2004, 75, 78–84.
  11. Van’t Hof RJ, Armour KJ, Smith LM Armour KE, Wei XQ, Liew FY et al.: Requirement of the inducible nitric oxide synthase pathway for Il-1 induced osteoclastic bone resorption. Proc Natl Acad Sci USA 2000, 97(14), 7993–7998.
  12. Calabrese EJ: Nitric oxide: Biphasic dose responses. Crit Rev Toxicol 2001, 31, 489–501.
  13. Riancho JA, Zarrabeitia MT, Fernandez Luna JL, Gonzalez Macias J: Mechanisms controlling nitric oxide synthesis in osteoblasts. Mol Cell Endocrinol 1995, 107, 87–92.
  14. Ozgocmen S, Kaya H, Fadillioglu E, Aydogan R, Yilmaz Z: Role of antioxidant systems, lipid peroxidation, and nitric oxide in postmenopausal osteoporosis. Mol Cell Biochem 2007, 295, 45–52.
  15. Korachich GB, Mishra OP: lipid peroxidation in rat brain cortical slices as measured by TBA test. J Neurochem 1980, 35, 1449–1452.
  16. Bathum L, von Bornemann Hjelmborg J, Christiansen L, Madsen JS, Skytthe A, Christensen K: Evidence for an association of methylene tetrahydrofolate reductase polymorphism C677T, an increased risk of fractures: results from a population-based Danish twin study. Osteoporos Int 2004, 15, 659–664.
  17. Villadsen MM, Bunger MH, Carstens M, Stenkjaer L, Langdahl BL: Methylene tetrahydrofolate reductase (MTHFR) C677T polymorphism is associated with osteoporotic vertebral fractures, but is a weak predictor of BMD. Osteoporos Int 2005, 16, 411–416.
  18. Perry HM 3rd, Bernard M, Horowitz M, Miller DK, Fleming S, Baker MZ et al.: The effect of aging on bone mineral metabolism and bone mass in Native American women. J Am Geriatr Soc 1998, 46(11), 1418–1422.
  19. The WHO Study Group: Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Osteoporos Int 1994, 4, 368–381.
  20. Buege JA, Aust SD: Microsomal lipid peroxidation. Methods Enzymol 1978, 52, 301–310.
  21. Cortas NK, Wakid NW: Determination of inorganic nitrate in serum and urine by a kinetic cadmium-reduction method. Clin Chem 1990, 36(8), 1440–1443.
  22. Bilgin HM, Tumer C, Diken H, Kelle M, Sermet A: Role of ghrelin in the regulation of gastric acid secretion involving nitrergic mechanisms in rats. Physiol Res 2008, 57(4), 563–568.
  23. Armour KE, Armour KJ, Gallagher ME, Gödecke A, Helfrich MH, Reid DM, Ralston SH: Defective bone formation and anabolic response to exogenous estrogen in mice with targeted disruption of endothelial nitric oxide synthase. Endocrinology 2001, 142(2), 760–766.
  24. Aguirre J, Buttery L, O’Shaughnessy M, Afzal F, Fernandez de Marticorena I, Hukkanen M et al.: Endothelial nitric oxide synthase gene-deficient mice demonstrate marked retardation in postnatal bone formation, reduced bone volume, and defects in osteoblast maturation and activity. Am J Pathol 2001, 158, 247–257.
  25. Hao YJ, Tang Y, Chen FB, Pei FX: Different Doses of Nitric Oxide Donor Prevent Osteoporosis in Ovariectomized Rats. Clin Orthop Relat Res 2005, 435, 226–231.
  26. Sontakke AN, Tare RS: A duality in the roles of reactive oxygen species with respect to bone metabolism. Clin Chim Acta 2002, 318, 145–148.
  27. Maggio D, Barabani M, Pierandrei M, Polidori MC, Catani M, Mecocci P et al.: Marked decrease in plasma antioxidants in aged osteoporotic women: results of a cross-sectional study. J Clin Endocrinol Metab 2003, 88(4), 1523–1527.
  28. Ravaglia G, Forti P, Maioli F, Servadei L, Martelli M, Brunetti N et al.: Folate, but not homocysteine, predicts the risk of fracture in elderly persons. J Gerontol A Biol Sci Med Sci 2005, 60, 1458–1462.
  29. Cagnacci A, Baldassari F, Rivolta G, Arangino S, Volpe A: Relation of homocysteine, folate, and vitamin B12 to bone mineral density of postmenopausal women. Bone 2003, 33(6), 956–959.
  30. Golbahar J, Hamidi A, Aminzadeh MA, Omrani GR: Association of plasma folate, plasma total homocysteine, but not methylenetetrahydrofolate reductase C667T polymorphism, with bone mineral density in postmenopausal Iranian women: a cross-sectional study. Bone 2004, 35, 760–765.
  31. Yılmaz N, Eren E: Homocysteine oxidative stress and relation to bone mineral density in postmenopausal osteoporosis. Aging Clin Exp Res 2009, 21, 353–357.
  32. Leboff MS, Narweker R, Lacroix A, Wu L, Jackson R, Lee J et al.: Homocysteine levels and risk of hip fracture in postmenopausal women. J Clin Endocrinol Metab 2009, 94(4), 1207–1213.
  33. Sato Y, Honda Y, Iwamoto J, Kanoko T, Satoh K: Effect of folate and mecobalamin on hip fractures in patients with stroke: a randomized controlled trial. J Am Med Assoc 2005, 293, 1082–1088.
  34. Van Meurs JB, Dhonukshe-Rutten RA, Pluijm SM, et al.: Homocysteine levels and the risk of osteoporotic fracture. N Engl J Med 2004, 350, 2033–2041.
  35. Herrmann W, Herrmann M: Is hyperhomocysteinemia a risk factor for osteoporosis? Expert Rev Endocrinol Metab 2008, 3(3), 309–313.
  36. Lenchik L, Kiebzak GM, Blunt BA: What is the role of serial bone mineral density measurements in patient management? J Clin Densitom 2002, 5, 29–38.
  37. Rasmussen LB, Ovesen L, Bülow I, Knudsen N, Laurberg P, Perrild H: Folate intake, lifestyle factors, and homocysteine concentrations in younger and older women. Am J Clin Nutr 2000, 72, 1156–1163.